No evidence that doping enhances athletic performance

December 10, 2012
No evidence that doping enhances athletic performance
Although use of recombinant human erythropoietin is prohibited among athletes because it reportedly enhances performance, there is no scientific evidence that it does so, according to a study published online Dec. 6 in the British Journal of Clinical Pharmacology.

(HealthDay)—Although use of recombinant human erythropoietin (rHuEPO) is prohibited among athletes because it reportedly enhances performance, there is no scientific evidence that it does so, according to a study published online Dec. 6 in the British Journal of Clinical Pharmacology.

Jules A.A.C. Heuberger, from Leiden University in the Netherlands, and colleagues reviewed 13 studies in the scientific and medical literature examining the effect of rHuEPO on .

The researchers found that no study specifically addressed . Most studies used forms of rHuEPO with half-lives similar to endogenous erythropoietin. Only eight studies were placebo controlled, and only five of these were reported to be double-blinded. Hemoglobin concentration, hematocrit, and increased after rHuEPO treatment. However, the authors note that the only parameters associated with enhanced performance are lactate threshold, respiratory compensation point, and work economy. In addition, published case reports have linked rHuEPO to adverse cardiovascular effects among cyclists.

"rHuEPO use in cycling is rife but scientifically unsupported by evidence and its use in sports is medical malpractice," Heuberger and colleagues conclude. "The situation with rHuEPO use in athletes is analogous to the many forms of non-evidence-based treatments that exist in medical practice and which by common opinion should be refuted or confirmed by good clinical trials with real life end points."

Explore further: EPO doping in elite cycling: No evidence of benefit, but high risk of harm

More information: Abstract
Full Text

Related Stories

EPO doping in elite cycling: No evidence of benefit, but high risk of harm

December 5, 2012
The drug erythropoietin, often called EPO, is banned from sports because it is believed to enhance an athlete's performance and give people who use it an unfair advantage over unenhanced competitors. However a new systemic ...

The challenges and rewards of Paralympic medicine

July 5, 2012
In the Lancet paper, "Paralympic medicine," Nick Webborn of the British Paralympic Association and Peter Van de Vliet of the International Paralympic Committee Medical and Scientific Department, outline some of the issues ...

Asthma is the most common chronic disease among Olympic athletes

July 31, 2012
Based on data from the last five Olympic games, a study by the University of Western Australia has identified those athletes with asthma and airway hyper-responsiveness. With a prevalence of around 8% they are the most common ...

Higher pain tolerance in athletes may hold clues for pain management

May 17, 2012
Stories of athletes bravely "playing through the pain" are relatively common and support the widespread belief that they experience pain differently than non-athletes. Yet, the scientific data on pain perception in athletes ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.